References

  1. US Food and Drug Administration. FDA approves first biosimilar for the treatment of certain breast and stomach cancers. Accessed on: August 11, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilartreatment-certain-breast-and-stomach-cancers
  2. Waller CF, Manikhas A, Pennella EJ, et al. Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial. J Clin Oncol. 2019;37(15_suppl):1021-1021.
  3. US Food and Drug Administration. Drug Approval Package: OGIVRI (trastuzumab-dkst). Summary Review. Accessed August 11, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761074Orig1s000TOC.cfm
  4. US Food and Drug Administration. Biosimilars Action Plan: Balancing Innovation and Competition. Accessed August 11, 2023. https://www.fda.gov/media/114574/download
  5. Schneider CK, Vleminckx C, Gravanis I, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol. 2012;30(12):1179–1185.
  6. Kozlowski S, Woodcock J, Midthun K, et al. Developing the Nation’s biosimilars program. N Engl J Med. 2011;365(5):385–388.
  7. US Food and Drug Administration. Briefing document: Oncologic Drugs Advisory Committee Meeting, July 13, 2017 BLA 761074 MYL-1401O, a proposed biosimilar to Herceptin (trastuzumab). Accessed on: August 11, 2023. https://www.fda.gov/media/106566/download
  8. Waller CF, Vutikullird A, Lawrence TE, et al. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab. Br J Clin Pharmacol. 2018;84(10):2336–2343.
  9. Kozlowski S, et al. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-8.
  10. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. JAMA. 2017;317(1):37–47.
  11. Burstein HJ, Schrag D. Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017;317(1):30–32.
  12. Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial. Accessed August 11, 2023. https://meetinglibrary.asco.org/record/172332/abstract
  13. Fasola G, Aprile G, Marini L, et al. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57